{
  "id": 8379,
  "date": "2019-04-23T14:34:49",
  "date_gmt": "2019-04-23T14:34:49",
  "guid": { "rendered": "./?p=8379" },
  "modified": "2019-04-23T14:34:49",
  "modified_gmt": "2019-04-23T14:34:49",
  "slug": "regulatory-times-march-2019",
  "status": "publish",
  "type": "post",
  "link": "./blog/regulatory-times-march-2019/",
  "title": { "rendered": "The Regulatory Times &#8211; March 2019" },
  "content": {
    "rendered": "<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-bottom: 0px;margin-top: 0px;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:0px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><ul class=\"fusion-checklist fusion-checklist-1\" style=\"font-size:13px;line-height:22.1px;\"><li class=\"fusion-li-item\"><span style=\"height:22.1px;width:22.1px;margin-right:9.1px;\" class=\"icon-wrapper circle-no\"><i class=\"fusion-li-icon fa fa-arrow-left\" style=\"color:#b21f74;\" aria-hidden=\"true\"></i></span><div class=\"fusion-li-item-content\" style=\"margin-left:31.2px;\">\n<p><a href=\"./blog/\">Back to Kinapse blog</a></p>\n</div></li></ul><div class=\"fusion-clearfix\"></div></div></div></div></div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;padding-top:0px;padding-right:0px;padding-bottom:0px;padding-left:0px;margin-bottom: 0px;margin-top: 0px;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#253745;padding: 3% 0px 0px 0px;\"><style type=\"text/css\"></style><div class=\"fusion-title title fusion-title-1 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"margin-top:20px;margin-right:0px;margin-bottom:15px;margin-left:0px;\"><h2 class=\"title-heading-left\" style=\"margin:0;\"><h1 style=\"text-align: center;\"><span style=\"color: #ffffff;\">The Regulatory Times</span></h1></h2></div><div class=\"fusion-text fusion-text-1\"><h6 style=\"text-align: center;\"><span style=\"color: #ffffff;\">March 2019</span></h6>\n</div><div class=\"fusion-text fusion-text-2\"><p style=\"text-align: center;\"><span style=\"color: #f2f2f2;\">Your monthly round-up of international Life Sciences regulatory news from the past month</span></p>\n</div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#b21f74;padding: 0.5% 0px 0px 0px;\"><style type=\"text/css\"></style><div class=\"fusion-title title fusion-title-2 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"margin-top:20px;margin-right:0px;margin-bottom:15px;margin-left:0px;\"><h2 class=\"title-heading-left\" style=\"margin:0;\"><p style=\"text-align: center;\"><span style=\"color: #ffffff;\">US</span></p></h2></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#f2f2f2;padding: 0px 0px 0px 0px;\"><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-0 fusion_builder_column_inner_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 4% 2% 0px 2%;\"><div class=\"fusion-text fusion-text-3\"><p><span style=\"color: #1d866c;\"><strong>Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act</strong></span></p>\n<p>This guidance explains the FDA\u2019s policy for evaluating bulk drug substances nominated for use in compounding by outsourcing facilities registered under section 503B of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Section 503B of the FD&amp;C Act directs the FDA to develop a list of bulk drug substances for which there is a clinical need (the 503B Bulks List). Drug products compounded using bulk drug substances on the 503B Bulks list qualify for certain exemptions from the FD&amp;C Act, provided the other conditions in section 503B are met. This guidance addresses FDA policies for developing the 503B Bulks List, including the Agency\u2019s interpretation of the phrase \u2018bulk drug substances for which there is a clinical need\u2019, as it is used in section 503B. This guidance also addresses the factors and processes by which the Agency intends to evaluate and list bulk drug substances.</p>\n<p>Drug products compounded under the conditions in section 503B are not exempt from current good manufacturing practice (CGMP) requirements in section 501(a)(2)(B) of the FD&amp;C Act.</p>\n<p>Bulk drug substances used in compounding under section 503B must also meet certain other statutory requirements, including the following:</p>\n<ol>\n<li>If an applicable monograph exists under the United States Pharmacopeia (USP), National Formulary (NF), or another compendium or pharmacopeia recognized by the Secretary under section 503B, the bulk drug substance must comply with the monograph;</li>\n<li>The bulk drug substance must be manufactured by an analysis.</li>\n</ol>\n<p>A more detailed discussion of the analysis is included in this guidance to evaluate bulk drug substances that have been nominated for inclusion on the 503B Bulks list.</p>\n<p><em>For details please refer to the link provided below:</em></p>\n<p><a href=\"https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM602276.pdf\"><span style=\"color: #b21f74;\"><strong>FDA Website</strong></span></a></p>\n</div><div class=\"fusion-clearfix\"></div></div></div></div><div class=\"fusion-sep-clear\"></div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;width:100%;max-width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#ffffff;border-top-width:30px;\"></div></div><div class=\"fusion-sep-clear\"></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#b21f74;padding: 0.5% 0px 0px 0px;\"><style type=\"text/css\"></style><div class=\"fusion-title title fusion-title-3 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"margin-top:20px;margin-right:0px;margin-bottom:15px;margin-left:0px;\"><h2 class=\"title-heading-left\" style=\"margin:0;\"><p style=\"text-align: center;\"><span style=\"color: #ffffff;\">EU</span></p></h2></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_2 1_2 fusion-one-half fusion-column-first\" style=\"width:50%;width:calc(50% - ( ( 4% ) * 0.5 ) );margin-right: 4%;margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#f2f2f2;padding: 0px 0px 0px 0px;\"><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-1 fusion_builder_column_inner_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 4% 2% 0px 2%;\"><div class=\"fusion-text fusion-text-4\"><p><span style=\"color: #1d866c;\"><strong>Regulatory Information &#8211; Adjusted Fees for Applications to EMA from the 1st of April 2019</strong></span></p>\n<p>The EMA reminds applicants and marketing authorisation holders that adjusted fees for all applications, except for pharmacovigilance procedures, will be coming into effect on the 1<sup>st</sup> of April 2019.</p>\n<p>Every year, the European Commission (EC) adopts a regulation that adjusts the fees payable to the Agency with reference to the inflation rate in the EU for the previous year. The 2018 inflation rate was 1.7%.</p>\n<p>The EMA will publish full details of the revised fees at the end of March, once the regulation has been adopted by the EC and publish in the Official Journal of the EU. The Agency&#8217;s Management Board will decide on the implementation of the regulation at its March 2019 meeting.</p>\n<p>Fees charged for pharmacovigilance procedures in accordance with Regulation (EU) 658/2014 are expected to be revised in 2020, taking into account the 2018 and 2019 inflation rates.</p>\n<p><em>Follow the </em><em>link for full details:</em></p>\n<p><a href=\"https://www.ema.europa.eu/en/news/regulatory-information-adjusted-fees-applications-ema-1-april-2019\"><strong>EMA Website</strong></a></p>\n</div><div class=\"fusion-clearfix\"></div></div></div></div><div class=\"fusion-sep-clear\"></div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;width:100%;max-width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#ffffff;border-top-width:30px;\"></div></div><div class=\"fusion-sep-clear\"></div><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-2 fusion_builder_column_inner_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 4% 2% 0px 2%;\"><div class=\"fusion-text fusion-text-5\"><p><span style=\"color: #1d866c;\"><strong>First Guidance on New Rules for Certain Medical Devices</strong></span></p>\n<p>The EMA published the first in a series of guidance documents to help applicants prepare for obligations stemming from the new EU regulations on medical devices.</p>\n<p>The new regulations introduce new roles and responsibilities for the EMA and national competent authorities (NCAs) in relation to certain types of medical devices and in-vitro diagnostics. The Agency is working closely with the EU regulatory network and with stakeholders from the pharmaceutical and medical device industries, including notified bodies, to ensure a smooth transition to the new regulatory framework.</p>\n<p><em>Follow the </em><em>link for full details:</em></p>\n<p><a href=\"https://www.ema.europa.eu/en/news/first-guidance-new-rules-certain-medical-devices\"><strong>EMA Website</strong></a></p>\n</div><div class=\"fusion-clearfix\"></div></div></div></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_2 1_2 fusion-one-half fusion-column-last\" style=\"width:50%;width:calc(50% - ( ( 4% ) * 0.5 ) );margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#f2f2f2;padding: 0px 0px 0px 0px;\"><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-3 fusion_builder_column_inner_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 4% 2% 0px 2%;\"><div class=\"fusion-text fusion-text-6\"><p><span style=\"color: #1d866c;\"><strong>EMA now operating from Amsterdam</strong></span></p>\n<p>As of the 13<sup>th</sup> March 2019, the EMA is operating from Amsterdam. The EMA left its London premises on the 1<sup>st</sup> March, and following a transitional week of teleworking, its staff will gradually move throughout this week into the Spark building in Amsterdam Sloterdijk.</p>\n<p><em>Follow the link for full details:</em></p>\n<p><a href=\"https://www.ema.europa.eu/en/news/ema-now-operating-amsterdam\"><strong>EMA Website</strong></a></p>\n</div><div class=\"fusion-clearfix\"></div></div></div></div><div class=\"fusion-sep-clear\"></div><div class=\"fusion-separator fusion-full-width-sep\" style=\"margin-left: auto;margin-right: auto;width:100%;max-width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#ffffff;border-top-width:30px;\"></div></div><div class=\"fusion-sep-clear\"></div><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-4 fusion_builder_column_inner_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 4% 2% 0px 2%;\"><div class=\"fusion-text fusion-text-7\"><p><span style=\"color: #1d866c;\"><strong>Notification of Request for a Time-Limited Exemption to Continue Batch Control Testing in the United Kingdom after their Withdrawal from the EU for a Nationally Authorised Medicinal Product</strong></span></p>\n<p>The CMDh has agreed a template for a \u201cNotification of request for a time-limited exemption to continue batch control testing in the United Kingdom after their withdrawal from the EU for a nationally authorised medicinal product\u201d to be used by Market Authorisation Holders. Details on the process to be followed have been included in the \u201cPractical guidance for procedures related to Brexit for medicinal products for human use approved via MRP/DCP\u201d. The practical guidance has further been updated to align it to the relevant document related to centrally authorised products, as far as possible, and to reflect recent CMDh agreements related to Brexit. All documents (communication from the European Commission, template to request batch control testing exemption and updated practical guidance related to Brexit) have been published on the CMDh website under \u201cBrexit\u201d.</p>\n<p><em>Follow the </em><em>link for full details:</em></p>\n<p><a href=\"http://www.hma.eu/535.html#c6449\"><strong>HMA Website</strong></a></p>\n</div><div class=\"fusion-clearfix\"></div></div></div></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#b21f74;padding: 0.5% 0px 0px 0px;\"><style type=\"text/css\"></style><div class=\"fusion-title title fusion-title-4 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"margin-top:20px;margin-right:0px;margin-bottom:15px;margin-left:0px;\"><h2 class=\"title-heading-left\" style=\"margin:0;\"><p style=\"text-align: center;\"><span style=\"color: #ffffff;\">Emerging Markets</span></p></h2></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;padding: 0.5% 0px 0px 0px;\"><style type=\"text/css\"></style><div class=\"fusion-title title fusion-title-5 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"margin-top:20px;margin-right:0px;margin-bottom:15px;margin-left:0px;\"><h2 class=\"title-heading-left\" style=\"margin:0;\"><p style=\"text-align: center;\"><span style=\"color: #b21f74;\">India</span></p></h2></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#f2f2f2;padding: 0px 0px 0px 0px;\"><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-5 fusion_builder_column_inner_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 4% 2% 0px 2%;\"><div class=\"fusion-text fusion-text-8\"><p><span style=\"color: #1d866c;\"><strong>The Drugs and Cosmetics (Third Amendment) Rules, 2013</strong></span></p>\n<p>The rules for ethics committees set forth the required composition of an ethics committee and list the information that must be included in the registration application, such as whether the committee has been audited or inspected and if so by whom. The CDSCO is to verify compliance with the rules governing ethics committees.</p>\n<p>In order to streamline the submission of applications for registration of Ethics Committees and their examination, it has been decided to introduce a system of preliminary scrutiny of such applications at the time of their receipt to determine their acceptability for examination by the CDSCO.</p>\n<p><em>Follow the link below for full details:</em></p>\n<p><a href=\"https://cdsco.gov.in/opencms/opencms/en/Clinical-Trial/Ethics-Committee/\"><strong>CDSCO\u00a0Website</strong></a></p>\n</div><div class=\"fusion-clearfix\"></div></div></div></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;padding: 0.5% 0px 0px 0px;\"><style type=\"text/css\"></style><div class=\"fusion-title title fusion-title-6 fusion-sep-none fusion-title-text fusion-title-size-two\" style=\"margin-top:20px;margin-right:0px;margin-bottom:15px;margin-left:0px;\"><h2 class=\"title-heading-left\" style=\"margin:0;\"><p style=\"text-align: center;\"><span style=\"color: #b21f74;\">Australia</span></p></h2></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#f2f2f2;padding: 0px 0px 0px 0px;\"><div class=\"fusion-builder-row fusion-builder-row-inner fusion-row\"><div class=\"fusion-layout-column fusion_builder_column_inner fusion-builder-nested-column-6 fusion_builder_column_inner_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 4% 2% 0px 2%;\"><div class=\"fusion-text fusion-text-9\"><p><span style=\"color: #1d866c;\"><strong>Brexit &#8211; Implications for Therapeutic Goods in Australia</strong></span></p>\n<p><strong>Brexit &#8216;no deal&#8217;</strong></p>\n<p>Regarding medical devices, if there is a &#8216;no deal&#8217; Brexit, the TGA will continue accepting conformity assessment documents issued by UK notified bodies for existing products while these remain current for the purposes of UK market authorisation. This will apply to both existing Australian Register of Therapeutic Goods (ARTG) entries and applications for new inclusions of medical devices in ARTG.</p>\n<p>For medicines, in the event of a Brexit &#8216;no deal&#8217;, there will be no impact on the supply of medicines to Australia from the UK. Under the UK-Australia MRA on Conformity Assessment, existing arrangements will continue whereby, the TGA will accept batch certification on MHRA Certificates for supply of medicines from the UK to the Australian Market.</p>\n<p><strong>Brexit &#8216;deal&#8217; or exit extension</strong></p>\n<p>For medical devices, under the proposed Brexit &#8216;deal&#8217;, UK notified bodies would continue to be recognised for a transition period through to 31 December 2020, so there will be no immediate impact on manufacturers certified by these notified bodies.</p>\n<p>For medicines, under the proposed Brexit &#8216;deal&#8217;, there will be no immediate impact on the supply of medicines to Australia from the UK. The existing arrangements will continue under the UK-Australia MRA as under the EU-Australia MRA. Similarly, if the timeframe for the exit of the UK from the EU is extended, current arrangements will continue, under the EU-Australia MRA, until an exit occurs.</p>\n<p><em>Follow the link below for full details:</em></p>\n<p><a href=\"https://www.tga.gov.au/brexit-implications-therapeutic-goods-australia\"><strong>TGA\u00a0Website</strong></a></p>\n</div><div class=\"fusion-clearfix\"></div></div></div></div><div class=\"fusion-clearfix\"></div></div></div></div></div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;padding-top:3%;padding-right:0px;padding-bottom:3%;padding-left:0px;margin-bottom: 0px;margin-top: 0px;border-width: 0px 0px 0px 0px;border-color:#eae9e9;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-12 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-first\" style=\"width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-right: 4%;margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-13 fusion_builder_column_2_3 2_3 fusion-two-third\" style=\"width:66.666666666667%;width:calc(66.666666666667% - ( ( 4% + 4% ) * 0.66666666666667 ) );margin-right: 4%;margin-top:0px;margin-bottom:30px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><style type=\"text/css\"></style><div class=\"fusion-title title fusion-title-7 fusion-sep-none fusion-title-text fusion-title-size-one\" style=\"margin-top:0px;margin-right:0px;margin-bottom:10px;margin-left:0px;\"><h1 class=\"title-heading-left\" style=\"margin:0;\"><h5><span style=\"color: #000000;\">Share this page:</span></h5></h1></div><div class=\"fusion-widget-area fusion-widget-area-1 fusion-content-widget-area\"><style type=\"text/css\">.fusion-widget-area-1 {padding:0px 0px 0px 0px;}.fusion-widget-area-1 .widget h4 {color:#333c4e;}.fusion-widget-area-1 .widget .heading h4 {color:#333c4e;}.fusion-widget-area-1 .widget h4 {font-size:18px;}.fusion-widget-area-1 .widget .heading h4 {font-size:18px;}</style><div class='the_champ_sharing_container the_champ_horizontal_sharing' data-super-socializer-href=\"./wp-json/wp/v2/posts/8379\"><div id=\"thechamphorizontalsharing-2\" class=\"widget widget_thechamphorizontalsharing\"><div class=\"the_champ_sharing_ul\"><a class=\"the_champ_button_linkedin\" href=\"https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2F#%2Fwp-json%2Fwp%2Fv2%2Fposts%2F8379&title=Kinapse%20website%20-%20Kinapse%20website\" title=\"Linkedin\" rel=\"nofollow noopener\" target=\"_blank\" style=\"font-size:24px!important;box-shadow:none;display:inline-block;vertical-align:middle\"><span class=\"the_champ_svg the_champ_s__default the_champ_s_linkedin\" style=\"background-color:#0077b5;width:35px;height:35px;border-radius:999px;display:inline-block;opacity:1;float:left;font-size:24px;box-shadow:none;display:inline-block;font-size:16px;padding:0 4px;vertical-align:middle;background-repeat:repeat;overflow:hidden;padding:0;cursor:pointer;box-sizing:content-box\"><svg style=\"display:block;border-radius:999px;\" focusable=\"false\" aria-hidden=\"true\" xmlns=\"http://www.w3.org/2000/svg\" width=\"100%\" height=\"100%\" viewBox=\"0 0 32 32\"><path d=\"M6.227 12.61h4.19v13.48h-4.19V12.61zm2.095-6.7a2.43 2.43 0 0 1 0 4.86c-1.344 0-2.428-1.09-2.428-2.43s1.084-2.43 2.428-2.43m4.72 6.7h4.02v1.84h.058c.56-1.058 1.927-2.176 3.965-2.176 4.238 0 5.02 2.792 5.02 6.42v7.395h-4.183v-6.56c0-1.564-.03-3.574-2.178-3.574-2.18 0-2.514 1.7-2.514 3.46v6.668h-4.187V12.61z\" fill=\"#FFF\"></path></svg></span></a><a class=\"the_champ_button_twitter\" href=\"https://twitter.com/intent/tweet?text=The%20Regulatory%20Times%20-%20March%202019&url=https%3A%2F%2F#%2Fwp-json%2Fwp%2Fv2%2Fposts%2F8379\" title=\"Twitter\" rel=\"nofollow noopener\" target=\"_blank\" style=\"font-size:24px!important;box-shadow:none;display:inline-block;vertical-align:middle\"><span class=\"the_champ_svg the_champ_s__default the_champ_s_twitter\" style=\"background-color:#55acee;width:35px;height:35px;border-radius:999px;display:inline-block;opacity:1;float:left;font-size:24px;box-shadow:none;display:inline-block;font-size:16px;padding:0 4px;vertical-align:middle;background-repeat:repeat;overflow:hidden;padding:0;cursor:pointer;box-sizing:content-box\"><svg style=\"display:block;border-radius:999px;\" focusable=\"false\" aria-hidden=\"true\" xmlns=\"http://www.w3.org/2000/svg\" width=\"100%\" height=\"100%\" viewBox=\"-4 -4 39 39\"><path d=\"M28 8.557a9.913 9.913 0 0 1-2.828.775 4.93 4.93 0 0 0 2.166-2.725 9.738 9.738 0 0 1-3.13 1.194 4.92 4.92 0 0 0-3.593-1.55 4.924 4.924 0 0 0-4.794 6.049c-4.09-.21-7.72-2.17-10.15-5.15a4.942 4.942 0 0 0-.665 2.477c0 1.71.87 3.214 2.19 4.1a4.968 4.968 0 0 1-2.23-.616v.06c0 2.39 1.7 4.38 3.952 4.83-.414.115-.85.174-1.297.174-.318 0-.626-.03-.928-.086a4.935 4.935 0 0 0 4.6 3.42 9.893 9.893 0 0 1-6.114 2.107c-.398 0-.79-.023-1.175-.068a13.953 13.953 0 0 0 7.55 2.213c9.056 0 14.01-7.507 14.01-14.013 0-.213-.005-.426-.015-.637.96-.695 1.795-1.56 2.455-2.55z\" fill=\"#FFF\"></path></svg></span></a><a class=\"the_champ_facebook\" href=\"https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2F#%2Fwp-json%2Fwp%2Fv2%2Fposts%2F8379\" title=\"Facebook\" rel=\"nofollow noopener\" target=\"_blank\" style=\"font-size:24px!important;box-shadow:none;display:inline-block;vertical-align:middle\"><span class=\"the_champ_svg\" style=\"background-color:#3c589a;width:35px;height:35px;border-radius:999px;display:inline-block;opacity:1;float:left;font-size:24px;box-shadow:none;display:inline-block;font-size:16px;padding:0 4px;vertical-align:middle;background-repeat:repeat;overflow:hidden;padding:0;cursor:pointer;box-sizing:content-box\"><svg style=\"display:block;border-radius:999px;\" focusable=\"false\" aria-hidden=\"true\" xmlns=\"http://www.w3.org/2000/svg\" width=\"100%\" height=\"100%\" viewBox=\"-5 -5 42 42\"><path d=\"M17.78 27.5V17.008h3.522l.527-4.09h-4.05v-2.61c0-1.182.33-1.99 2.023-1.99h2.166V4.66c-.375-.05-1.66-.16-3.155-.16-3.123 0-5.26 1.905-5.26 5.405v3.016h-3.53v4.09h3.53V27.5h4.223z\" fill=\"#FFF\"></path></svg></span></a><a class=\"the_champ_more\" title=\"More\" rel=\"nofollow noopener\" style=\"font-size:24px!important;border:0;box-shadow:none;display:inline-block!important;font-size:16px;padding:0 4px;vertical-align: middle;display:inline;\" href=\"./wp-json/wp/v2/posts/8379\" onclick=\"event.preventDefault()\"><span class=\"the_champ_svg\" style=\"background-color:#ee8e2d;width:35px;height:35px;border-radius:999px;display:inline-block!important;opacity:1;float:left;font-size:32px!important;box-shadow:none;display:inline-block;font-size:16px;padding:0 4px;vertical-align:middle;display:inline;background-repeat:repeat;overflow:hidden;padding:0;cursor:pointer;box-sizing:content-box;\" onclick=\"theChampMoreSharingPopup(this, './wp-json/wp/v2/posts/8379', 'Kinapse%20website%20-%20Kinapse%20website', 'The%20Regulatory%20Times%20-%20March%202019' )\"><svg xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" viewBox=\"-.3 0 32 32\" version=\"1.1\" width=\"100%\" height=\"100%\" style=\"display:block;border-radius:999px;\" xml:space=\"preserve\"><g><path fill=\"#FFF\" d=\"M18 14V8h-4v6H8v4h6v6h4v-6h6v-4h-6z\" fill-rule=\"evenodd\"></path></g></svg></span></a></div></div></div><div class=\"fusion-additional-widget-content\"></div></div><div class=\"fusion-clearfix\"></div></div></div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-14 fusion_builder_column_1_6 1_6 fusion-one-sixth fusion-column-last\" style=\"width:16.666666666667%;width:calc(16.666666666667% - ( ( 4% + 4% ) * 0.16666666666667 ) );margin-top:0px;margin-bottom:0px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\"><div class=\"fusion-clearfix\"></div></div></div></div></div></p>\n",
    "protected": false
  },
  "excerpt": {
    "rendered": "<p>Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March&#8217;s edition from Kinapse.</p>\n",
    "protected": false
  },
  "author": 14,
  "featured_media": 8405,
  "comment_status": "open",
  "ping_status": "open",
  "sticky": false,
  "template": "",
  "format": "standard",
  "meta": { "_mi_skip_tracking": false },
  "categories": [35],
  "tags": [],
  "acf": [],
  "yoast_head": "<!-- This site is optimized with the Yoast SEO plugin v19.9 - https://yoast.com/wordpress/plugins/seo/ -->\n<title>Kinapse blog | The Regulatory Times - March 2019</title>\n<meta name=\"description\" content=\"Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March&#039;s edition from Kinapse.\" />\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" />\n<link rel=\"canonical\" href=\"./blog/regulatory-times-march-2019/\" />\n<meta property=\"og:locale\" content=\"en_GB\" />\n<meta property=\"og:type\" content=\"article\" />\n<meta property=\"og:title\" content=\"The Regulatory Times - March 2019\" />\n<meta property=\"og:description\" content=\"Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March&#039;s edition from Kinapse.\" />\n<meta property=\"og:url\" content=\"./blog/regulatory-times-march-2019/\" />\n<meta property=\"og:site_name\" content=\"Kinapse website\" />\n<meta property=\"article:published_time\" content=\"2019-04-23T14:34:49+00:00\" />\n<meta property=\"og:image\" content=\"./wp-content/uploads/2019/04/The-Regulatory-Times-March-2019-e1556029261265.jpg\" />\n\t<meta property=\"og:image:width\" content=\"1200\" />\n\t<meta property=\"og:image:height\" content=\"800\" />\n\t<meta property=\"og:image:type\" content=\"image/jpeg\" />\n<meta name=\"author\" content=\"Ed Ricketts\" />\n<meta name=\"twitter:card\" content=\"summary_large_image\" />\n<meta name=\"twitter:title\" content=\"The Regulatory Times - March 2019\" />\n<meta name=\"twitter:description\" content=\"Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March&#039;s edition from Kinapse.\" />\n<meta name=\"twitter:image\" content=\"./wp-content/uploads/2019/04/The-Regulatory-Times-March-2019-e1556029261265.jpg\" />\n<meta name=\"twitter:label1\" content=\"Written by\" />\n\t<meta name=\"twitter:data1\" content=\"Ed Ricketts\" />\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" />\n\t<meta name=\"twitter:data2\" content=\"19 minutes\" />\n<script type=\"application/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https://schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"./blog/regulatory-times-march-2019/\",\"url\":\"./blog/regulatory-times-march-2019/\",\"name\":\"Kinapse blog | The Regulatory Times - March 2019\",\"isPartOf\":{\"@id\":\"./#website\"},\"datePublished\":\"2019-04-23T14:34:49+00:00\",\"dateModified\":\"2019-04-23T14:34:49+00:00\",\"author\":{\"@id\":\"./#/schema/person/f746367cd3256d31f7d02a01ad60b3b6\"},\"description\":\"Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March's edition from Kinapse.\",\"breadcrumb\":{\"@id\":\"./blog/regulatory-times-march-2019/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"./blog/regulatory-times-march-2019/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"./blog/regulatory-times-march-2019/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"./\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Regulatory Times &#8211; March 2019\"}]},{\"@type\":\"WebSite\",\"@id\":\"./#website\",\"url\":\"./\",\"name\":\"Kinapse website\",\"description\":\"Kinapse website\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"./?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"./#/schema/person/f746367cd3256d31f7d02a01ad60b3b6\",\"name\":\"Ed Ricketts\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"./#/schema/person/image/\",\"url\":\"https://secure.gravatar.com/avatar/5e1d661561924b8b0b03c2463d26825d?s=96&d=mm&r=g\",\"contentUrl\":\"https://secure.gravatar.com/avatar/5e1d661561924b8b0b03c2463d26825d?s=96&d=mm&r=g\",\"caption\":\"Ed Ricketts\"},\"sameAs\":[\"http://#\"],\"url\":\"./author/ed-ricketts/\"}]}</script>\n<!-- / Yoast SEO plugin. -->",
  "yoast_head_json": {
    "title": "Kinapse blog | The Regulatory Times - March 2019",
    "description": "Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March's edition from Kinapse.",
    "robots": {
      "index": "index",
      "follow": "follow",
      "max-snippet": "max-snippet:-1",
      "max-image-preview": "max-image-preview:large",
      "max-video-preview": "max-video-preview:-1"
    },
    "canonical": "./blog/regulatory-times-march-2019/",
    "og_locale": "en_GB",
    "og_type": "article",
    "og_title": "The Regulatory Times - March 2019",
    "og_description": "Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March's edition from Kinapse.",
    "og_url": "./blog/regulatory-times-march-2019/",
    "og_site_name": "Kinapse website",
    "article_published_time": "2019-04-23T14:34:49+00:00",
    "og_image": [
      {
        "width": 1200,
        "height": 800,
        "url": "./wp-content/uploads/2019/04/The-Regulatory-Times-March-2019-e1556029261265.jpg",
        "type": "image/jpeg"
      }
    ],
    "author": "Ed Ricketts",
    "twitter_card": "summary_large_image",
    "twitter_title": "The Regulatory Times - March 2019",
    "twitter_description": "Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March's edition from Kinapse.",
    "twitter_image": "./wp-content/uploads/2019/04/The-Regulatory-Times-March-2019-e1556029261265.jpg",
    "twitter_misc": {
      "Written by": "Ed Ricketts",
      "Estimated reading time": "19 minutes"
    },
    "schema": {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": "WebPage",
          "@id": "./blog/regulatory-times-march-2019/",
          "url": "./blog/regulatory-times-march-2019/",
          "name": "Kinapse blog | The Regulatory Times - March 2019",
          "isPartOf": { "@id": "./#website" },
          "datePublished": "2019-04-23T14:34:49+00:00",
          "dateModified": "2019-04-23T14:34:49+00:00",
          "author": {
            "@id": "./#/schema/person/f746367cd3256d31f7d02a01ad60b3b6"
          },
          "description": "Your monthly round-up of international Life Sciences regulatory news from the past month. Follow the link to read March's edition from Kinapse.",
          "breadcrumb": {
            "@id": "./blog/regulatory-times-march-2019/#breadcrumb"
          },
          "inLanguage": "en-GB",
          "potentialAction": [
            {
              "@type": "ReadAction",
              "target": ["./blog/regulatory-times-march-2019/"]
            }
          ]
        },
        {
          "@type": "BreadcrumbList",
          "@id": "./blog/regulatory-times-march-2019/#breadcrumb",
          "itemListElement": [
            {
              "@type": "ListItem",
              "position": 1,
              "name": "Home",
              "item": "./"
            },
            {
              "@type": "ListItem",
              "position": 2,
              "name": "The Regulatory Times &#8211; March 2019"
            }
          ]
        },
        {
          "@type": "WebSite",
          "@id": "./#website",
          "url": "./",
          "name": "Kinapse website",
          "description": "Kinapse website",
          "potentialAction": [
            {
              "@type": "SearchAction",
              "target": {
                "@type": "EntryPoint",
                "urlTemplate": "./?s={search_term_string}"
              },
              "query-input": "required name=search_term_string"
            }
          ],
          "inLanguage": "en-GB"
        },
        {
          "@type": "Person",
          "@id": "./#/schema/person/f746367cd3256d31f7d02a01ad60b3b6",
          "name": "Ed Ricketts",
          "image": {
            "@type": "ImageObject",
            "inLanguage": "en-GB",
            "@id": "./#/schema/person/image/",
            "url": "https://secure.gravatar.com/avatar/5e1d661561924b8b0b03c2463d26825d?s=96&d=mm&r=g",
            "contentUrl": "https://secure.gravatar.com/avatar/5e1d661561924b8b0b03c2463d26825d?s=96&d=mm&r=g",
            "caption": "Ed Ricketts"
          },
          "sameAs": ["http://#"],
          "url": "./author/ed-ricketts/"
        }
      ]
    }
  },
  "_links": {
    "self": [{ "href": "./wp-json/wp/v2/posts/8379" }],
    "collection": [{ "href": "./wp-json/wp/v2/posts" }],
    "about": [{ "href": "./wp-json/wp/v2/types/post" }],
    "author": [
      { "embeddable": true, "href": "./wp-json/wp/v2/users/14" }
    ],
    "replies": [
      {
        "embeddable": true,
        "href": "./wp-json/wp/v2/comments?post=8379"
      }
    ],
    "version-history": [
      { "count": 7, "href": "./wp-json/wp/v2/posts/8379/revisions" }
    ],
    "predecessor-version": [
      {
        "id": 8407,
        "href": "./wp-json/wp/v2/posts/8379/revisions/8407"
      }
    ],
    "wp:featuredmedia": [
      { "embeddable": true, "href": "./wp-json/wp/v2/media/8405" }
    ],
    "wp:attachment": [{ "href": "./wp-json/wp/v2/media?parent=8379" }],
    "wp:term": [
      {
        "taxonomy": "category",
        "embeddable": true,
        "href": "./wp-json/wp/v2/categories?post=8379"
      },
      {
        "taxonomy": "post_tag",
        "embeddable": true,
        "href": "./wp-json/wp/v2/tags?post=8379"
      }
    ],
    "curies": [
      { "name": "wp", "href": "https://api.w.org/{rel}", "templated": true }
    ]
  }
}
